A detailed history of Wells Fargo & Company transactions in Champions Oncology, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 47 shares of CSBR stock, worth $237. This represents 0.0% of its overall portfolio holdings.

Number of Shares
47
Previous 46 2.17%
Holding current value
$237
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$4.9 - $6.91 $4 - $6
1 Added 2.17%
47 $0
Q4 2023

Feb 09, 2024

BUY
$4.56 - $6.59 $13 - $19
3 Added 6.98%
46 $0
Q3 2023

Nov 13, 2023

SELL
$5.2 - $7.32 $10 - $14
-2 Reduced 4.44%
43 $0
Q2 2023

Aug 15, 2023

BUY
$4.11 - $6.81 $8 - $13
2 Added 4.65%
45 $0
Q1 2023

May 12, 2023

BUY
$4.0 - $4.67 $4 - $4
1 Added 2.38%
43 $0
Q4 2022

Feb 13, 2023

BUY
$3.75 - $7.1 $3 - $7
1 Added 2.44%
42 $0
Q3 2022

Nov 14, 2022

SELL
$7.21 - $9.47 $21 - $28
-3 Reduced 6.82%
41 $0
Q2 2022

Aug 12, 2022

BUY
$6.81 - $8.31 $20 - $24
3 Added 7.32%
44 $0
Q1 2022

May 16, 2022

BUY
$7.26 - $8.53 $7 - $8
1 Added 2.5%
41 $0
Q3 2021

Nov 15, 2021

BUY
$9.11 - $10.96 $36 - $43
4 Added 11.11%
40 $0
Q2 2021

Aug 16, 2021

SELL
$8.45 - $11.72 $454,153 - $629,903
-53,746 Reduced 99.93%
36 $0
Q1 2021

May 13, 2021

BUY
$10.61 - $13.75 $461,004 - $597,437
43,450 Added 420.54%
53,782 $608,000
Q4 2020

Feb 09, 2021

SELL
$8.39 - $13.27 $34,138 - $53,995
-4,069 Reduced 28.25%
10,332 $112,000
Q3 2020

Nov 05, 2020

BUY
$7.05 - $10.2 $75,463 - $109,180
10,704 Added 289.53%
14,401 $133,000
Q2 2020

Aug 13, 2020

BUY
$6.65 - $9.84 $24,339 - $36,014
3,660 Added 9891.89%
3,697 $35,000
Q1 2020

May 14, 2020

BUY
$4.19 - $8.62 $155 - $318
37 New
37 $0

Others Institutions Holding CSBR

About CHAMPIONS ONCOLOGY, INC.


  • Ticker CSBR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 13,522,400
  • Market Cap $68.3M
  • Description
  • Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Techn...
More about CSBR
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.